

Modified Form PTO-1449	Atty. Docket No. A-451N	Serial No. 10/825,898
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Applicant Boyle	
	Filing Date April 15, 2004	Group

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1						
	A2						
	A3						
	A4						
	A5						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
/R.S./	B1	0 784 093 A1	1997-07-16	EP			
	B2						
	B3						
	B4						

OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

/R.S./	C1	Bharti and Aggarwal, "Ranking the role of RANK ligand in apoptosis", Apoptosis, 9: 677-690 (2004)
/R.S./	C2	Chopin et al., "Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21 waf1", Exp. Cell Res., 298: 560-573 (2004)
/R.S./	C3	Collin et al., "Constitutive expression of osteoclast-stimulating activity by normal clonal osteoblast-like cells: effects of parathyroid hormone and 1,25-dihydroxyvitamin D3", Endocrinology, 131(3): 1181-1187 (1992)
/R.S./	C4	Lacey et al., "Interleukin 4, interferon-gamma, and prostaglandin E impact the osteoclastic cell-forming potential of murine bone marrow macrophages", Endocrinology, 136(8): 2367-2376 (1995)
	C5	Roitt et al., Immunology, 3rd Ed., MOSBY, ISBN: 0-397-44765-5, (1993)
/R.S./	C6	Takahashi et al., "Osteoblastic cells are involved in osteoclast formation", Endocrinology, 123(5): 2600-2602 (1996)
/R.S./	C7	Theill et al., "RANK-L and RANK: T Cells, Bone Loss, and Mammalian Evolution", Annu. Rev. Immunol., 20: 795-823 (2002)
/R.S./	C8	Yasuda et al., "Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis in Vitro", Endocrinology, 139(3): 1329-1337 (1998)
	C9	Amendment and Response to Office Action Mailed September 19, 2008, filed March 10, 2009 for USSN 10/408,901
	C10	Notice of Allowance and Fee(s) Due Mailed September 28, 2009 for USSN 10/408,901
	C11	Part B - Issue Fee(s) Transmittal filed December 22, 2009 for USSN 10/408,901

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449

Atty. Docket No.

A-451N

Serial No.

10/825,898

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Boyle

Filing Date

April 15, 2004

Group

/R.S./	C12	Lacey et al., "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation", Cell, 93: 165-176 (1998)
	C13	Response to Notice of Noncompliant Amendment and Preliminary Amendment filed August 21, 2009 for USSN 09/791,153
	C14	Office Communication Mailed September 2, 2009 for USSN 11/981,664
	C15	Response filed December 2, 2009 for USSN 11/981,664 including extension of time, electronic fee transmittal, and electronic acknowledgement receipt
	C16	Office Communication Mailed February 2, 2010 for USSN 11/981,664
	C17	Response filed February 16, 2010 for USSN 09/211,297 including exhibits A through H (Shown above in C9-C16), extension of time, IDS and SB08a Form, RCE transmittal, electronic fee transmittal and electronic acknowledgement receipt

EXAMINER:

/Ronald Schwadron/

Date Considered:

11/30/2010

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.